ABBV:NYSEAbbVie Inc. Analysis
Data as of 2026-09-03 - not real-time
$260.69
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
At $260.69, AbbVie Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Across the trailing 30 sessions it gained 1.5%. RSI sits at 56.0, which reads as neutral, and MACD momentum is bearish. Watch $241.95 as support and $266.97 as the nearer resistance level.
Multiples put this in fair territory: 73.8 times earnings against the sector's 30.8. The average analyst target implies 6.1% above today's level. Revenue is growing at 10.2% on a 9.8% profit margin. The 2.64% dividend yield looks stretched against payout coverage.
On a 1-10 scale the risk profile lands at 3 — low. With 30-day volatility of 23.1%, a beta of -0.09 and a maximum drawdown of 19.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 3/10 conviction on the long call.
Multiples put this in fair territory: 73.8 times earnings against the sector's 30.8. The average analyst target implies 6.1% above today's level. Revenue is growing at 10.2% on a 9.8% profit margin. The 2.64% dividend yield looks stretched against payout coverage.
On a 1-10 scale the risk profile lands at 3 — low. With 30-day volatility of 23.1%, a beta of -0.09 and a maximum drawdown of 19.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 3/10 conviction on the long call.
Top Market Events
Pharmaceutical company AbbVie NYSE:ABBV in Q2 CY2026, with sales up 10.Pharmaceutical company AbbVie NYSE:ABBV beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.AbbVie Inc. NYSE:ABBV reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 228.23
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 73.8 versus sector average of 30.8
- Dividend yield of 2.64% looks stretched against payout coverage
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 73.8 versus sector average of 30.8
- Dividend yield of 2.64% looks stretched against payout coverage
- Analyst targets imply +6.1% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth10.20%
Profit Margin9.80%
P/E Ratio73.8
ROA10.51%
P/B Ratio-77.6
Op. Cash Flow$19.5B
Free Cash Flow$16.9B
Industry P/E30.8
Technical Analysis
TrendBullish
RSI56.0
Support$241.95
Resistance$266.97
MA 20$257.04
MA 50$254.22
MA 200$228.23
MACDBearish
VolumeDecreasing
Fear & Greed Index95.29
Valuation
Fair Value$148.63
Target Price$276.59
Upside/Downside6.10%
GradeFair
TypeBlend
Dividend Yield2.64%
Risk Assessment
Beta-0.09
Volatility23.09%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.